Tagged with Cell & Gene Therapy

France France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of expertise and increasing political support. However, financing and manufacturing French gene therapies is proving an issue, meaning that France is…

China The US FDA has granted orphan drug designation to Shanghai-headquartered biotech CARsgen Therapeutics’ CAR-T cell therapy CT053 for multiple myeloma after positive results were observed in the phase I trial efficacy evaluation.   19 of 24 patients with relapsed and refractory multiple myeloma showed complete response Zonghai Li, CARSgen Therapeutics…

Taiwan Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his future strategy for expanding the company’s position in the sector.   One of EMO’s missions is to help the government…

Taiwan HB Chen, president of TaiwanBio Therapeutics, introduces the innovative stem cell company and elaborates on their patented cell expansion technique for the production of mesenchymal stem cells (MSC). Chen then goes on to discuss the company’s innovative pipeline of stem cell therapies.   Overall, our offering will be a great…

Opinion Emanuele Ostuni, head of cell & gene therapy for Novartis Oncology in Europe, outlines how stakeholders across the biopharmaceutical value chain can surf the wave of innovation that breakthrough therapies such as CAR-T represent. Waves and Innovation CAR-T therapies are the frontrunners of a wave of amazing biomedical innovation Over…

Germany Bayer’s latest move to buy out BlueRock Therapeutics comes with a price tag of USD 600 million in total as the company increasingly looks toward cell and gene therapies to bolster its development pipeline and create transformative biotechnological solutions.   German pharmaceutical company Bayer AG is setting its sights on…

Cell & Gene Therapy Medicare, a national health insurance program in the United States covering Americans aged 65 and older as well as younger people with disabilities, has recently announced it will be increasing reimbursement rates and expanding coverage for cell and gene therapy treatments, good news for cancer patients and pharma companies Gilead…

USA PhRMA’s Anne McDonald Pritchett PhD highlights the remarkable development of cell and gene therapies in recent years and the three ways in which the US healthcare system can better accommodate them: creating manufacturing systems that take treatment timelines into account, a health system that values treatments based on patient outcomes,…

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) highlights why cell and gene therapies seem finally braced for mainstream adoption as well as the significant barriers that still need to be overcome for large patient numbers to access these innovative and often costly treatments.   Today, [ATMPs] finally seem to…

Opinion Rare diseases and cell and gene therapy executive recruitment specialist Steve Smith outlines six key strategies for attracting and retaining talent in these rapidly emerging fields.   In a young industry experiencing rapid growth, talent demand far outweighs supply Cell & Gene Therapy; “It’s no longer something people read about…

Opinion Frost & Sullivan’s Senior Research Analyst, Aarti Chitale looks at the sizeable impact that precision medicine, especially regenerative medicine, is already having on the global therapeutic landscape, and how the Asia-Pacific region is positioning itself at the forefront of this trend.   Providing the right treatment/ right drug at the…

USA Christopher P. Molineaux of Life Sciences Pennsylvania outlines the Keystone State’s rich lineage of pharmaceutical innovation, how the association is building inter-state and international connections, and why Philadelphia is justified in branding itself as the ‘Cellicon Valley’.   We are at the epicentre of cell and gene therapy, what we…